StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) company profile

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.36−0.63 (-3.71%)

Close on Nov 13, 2026Market cap $309.72MP/E –Yield –

About Scribe Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Scribe Therapeutics, Inc. is listed on Nasdaq under the ticker SCTX, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Scribe Therapeutics, Inc.
Headquarters
Alameda, CA
Address
1150 Marina Village Pkwy 94501
Phone
(510) 454-0213
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
SCTX
Exchange
Nasdaq
IPO date
Jul 27, 2026
Shares outstanding
19M, Aug 31, 2026
Filer category
<br>Emerging growth company
SEC CIK
1853921
CUSIP
811033109
ISIN
US8110331092
FIGI
BBG00RR3PF94
Share class FIGI
BBG00RR3PFD9
EIN
82-2157847

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Benjamin L. OakesPresident, CEO, Director506,602
David ParrotChief Financial Officer2,666
Svetlana LucasChief Business Officer33,695
Carl L. GordonDirector348,825
Advisors Llc OrbimedDirector348,825
Capital GP VIII LLC OrbiMedDirector–
Behzad AghazadehDirector–
Capital Advisors LLC AvoroDirector–
Ventures LLC AvoroDirector3,088,888
Joshua BleharskiDirector–
James Dean WatsonDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 27, 2026
Offer price
$15.00
Securities offered
8,580,000
Gross proceeds
$128.70M
Exchange
Nasdaq
First trading day
Jul 24, 2026
First-day close
$21.65+44.3%
Lock-up ends (est.)
Jan 20, 2027

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?